Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the P/S ratio high or low?
The P/S ratio of 9796.88 is in line with its estimated 1-year average of 9868.69, around the middle of its estimated 1-year range (8606.57–11320.35).
As of 2026-10-06T22:40:55.087Z.
Calculation as of: 2026-10-06T22:40:55.087Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: aba6dde202523e327e8df603f06c84cdc8b0caa676e2570b33753db7f555988b
Current P/S: FMP quote market capitalization / TTM revenue. Historical estimates use price and reported weighted-average shares; daily points use adjusted close × quarterly weighted-average shares / TTM revenue. Historical series through 2026-10-05.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
9796.88
PS RATIO AVG TTM
N/A
PS RATIO AVG 3Y
N/A
PS RATIO AVG 5Y
N/A
PS RATIO AVG 10Y
N/A
PS RATIO AVG 15Y
N/A
PS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
4.28
median of 578 covered companies
CURRENT VS SECTOR MEDIAN
+229066.78%
vs the sector median at left
Market Cap
$11.55M
PS Ratio
N/A
TTM Avg
98.45
3Y Avg
233.47
5Y Avg
371.43
Market Cap
$11.12M
PS Ratio
4.44
TTM Avg
60.10
3Y Avg
91.90
5Y Avg
110.40
Market Cap
$11.08M
PS Ratio
N/A
TTM Avg
3.04
3Y Avg
3.04
5Y Avg
6193.39
Market Cap
$11.02M
PS Ratio
110.19
TTM Avg
104.86
3Y Avg
73.15
5Y Avg
73.15
Market Cap
$11.00M
PS Ratio
N/A
TTM Avg
32.91
3Y Avg
62.07
5Y Avg
66.46
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Caring Brands, Inc. (CABR) | $11.36M | 9796.88 | N/A | N/A | N/A |
| Phio Pharmaceuticals Corp. (PHIO)vs › | $11.55M | N/A | 98.45 | 233.47 | 371.43 |
| VistaGen Therapeutics, Inc. (VTGN)vs › | $11.12M | 4.44 | 60.10 | 91.90 | 110.40 |
| Kiora Pharmaceuticals, Inc. (KPRX)vs › | $11.08M | N/A | 3.04 | 3.04 | 6193.39 |
| Lisata Therapeutics, Inc. (LSTA)vs › | $11.02M | 110.19 | 104.86 | 73.15 | 73.15 |
| CytoMed Therapeutics Limited (GDTC)vs › | $11.00M | N/A | 32.91 | 62.07 | 66.46 |
| IRIDEX Corporation (IRIX)vs › | $11.77M | 0.23 | 0.35 | 0.52 | 0.71 |
| Cerenome, Inc. (CNSY)vs › | $10.94M | 2.60 | 4.41 | 4.41 | 4.41 |
| BioVie Inc. (BIVI)vs › | $10.86M | N/A | N/A | N/A | N/A |
| Polyrizon Ltd. (PLRZ)vs › | $10.83M | N/A | N/A | N/A | N/A |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $740 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-09-30 |
| Q4 FY2025Period ended 2025-12-31 | $420 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-12-31 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-31 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-13 |
| TTM revenue | $1,160 |
Current P/S: $11,364,383 market capitalization ÷ $1,160 TTM revenue = 9796.88x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T20:00:00.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
At 9796.88, P/S is at an extreme level, where the multiple carries little signal — higher than 47% of readings in its estimated 1-year history.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
estimated 1-year low
8606.57
median
9924.69
estimated 1-year high
11320.35
P/S Ratio
9796.88
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PS RATIO |
|---|---|
| 2026-10-05 | 8761.64 |
| 2026-10-02 | 8994.25 |
| 2026-10-01 | 9226.86 |
| 2026-09-30 | 9226.86 |
| 2026-09-29 | 9459.47 |
| 2026-09-28 | 9614.55 |
| 2026-09-25 | 9614.55 |
| 2026-09-24 | 9459.47 |
| 2026-09-23 | 9692.08 |
| 2026-09-22 | 10157.30 |
| 2026-09-21 | 10079.77 |
| 2026-09-18 | 10855.13 |
| 2026-09-17 | 10467.45 |
| 2026-09-16 | 9459.47 |
| 2026-09-15 | 9149.33 |
| 2026-09-14 | 8994.25 |
| 2026-09-11 | 9226.86 |
| 2026-09-10 | 8839.18 |
| 2026-09-09 | 8684.11 |
| 2026-09-08 | 8606.57 |
| 2026-09-04 | 9769.62 |
| 2026-09-03 | 9847.16 |
| 2026-09-02 | 11320.35 |
| 2026-09-01 | 10467.45 |
| 2026-08-31 | 10389.91 |
| 2026-08-28 | 10777.60 |
| 2026-08-27 | 10700.06 |
| 2026-08-26 | 10312.38 |
| 2026-08-25 | 10002.23 |
| 2026-08-24 | 10467.45 |
| 2026-08-21 | 10002.23 |
| 2026-08-20 | 10312.38 |
| 2026-08-19 | 10777.60 |
| 2026-08-18 | 10544.99 |
| 2026-08-17 | 10312.38 |
| 2026-08-14 | 10700.06 |